B3GALT6 antibody (AA 229-329)

Catalog No. ABIN530579

The Mouse Monoclonal anti-B3GALT6 antibody has been validated for WB and ELISA. It is suitable to detect B3GALT6 in samples from Human. There is 1 publication available.

Quick Overview for B3GALT6 antibody (AA 229-329) (ABIN530579)

Target: B3GALT6 (UDP-Gal:betaGal beta 1,3-Galactosyltransferase Polypeptide 6 (B3GALT6))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This B3GALT6 antibody is un-conjugated

Application: Western Blotting (WB), ELISA

Clone: 3E5

Product Details anti-B3GALT6 Antibody

Binding Specificity: AA 229-329

Purpose: Mouse monoclonal antibody raised against a partial recombinant B3GALT6.

Sequence: RLSRDYLRAW HSEDVSLGAW LAPVDVQREH DPRFDTEYRS RGCSNQYLVT HKQSLEDMLE KHATLAREGR LCKREVQLRL SYVYDWSAPP SQCCQRREGI P

Cross-Reactivity: Human

Characteristics: Antibody Reactive Against Recombinant Protein.

Immunogen: B3GALT6 (NP_542172, 229 a.a. ~ 329 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.

Isotype: IgG2a

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Buffer: In 1x PBS, pH 7.4

Handling Advice: Aliquot to avoid repeated freezing and thawing.

Storage: -20 °C

Storage Comment: Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.

References for anti-B3GALT6 antibody (ABIN530579)

Dziedzic, Wegrzyn, Jakóbkiewicz-Banecka: "Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease." in: European journal of human genetics : EJHG, Vol. 18, Issue 2, pp. 200-5, (2010) (PubMed).

Target Details for B3GALT6

Target: B3GALT6 (UDP-Gal:betaGal beta 1,3-Galactosyltransferase Polypeptide 6 (B3GALT6))

Alternative Name: B3GALT6

Background: Full Gene Name: UDP-Gal:betaGal beta 1,3-galactosyltransferase polypeptide 6
Synonyms: beta3GalT6

Gene ID: 126792

NCBI Accession: NM_080605

Pathways: Glycosaminoglycan Metabolic Process